Advertisements


We are Sorry, This Page doesn't Exist


Viking Therapeutics stock rose 87% on results for its liver disease drug — and the company has more in store this fall

The company’s midstage clinical trial had positive results, and the condition in question affects an estimated 100 million people in the U.S......»»

Category: topSource: marketwatchSep 18th, 2018

Juno Therapeutics and investors reach settlement related to fatal drug trial

The $24 million mediated settlement stems from a string of patient deaths that nearly derailed Seattle's star biotech startup two years ago......»»

Category: topSource: bizjournalsSep 2nd, 2018

Ovid Therapeutics shares fall 28% as investors question new drug data (OVID)

Markets Insider New York-based biotech company Ovid Therapeutics announced on Monday positive phase 2 trial results for its treatment for a rare disease called Angelman Syndrom.....»»

Category: topSource: businessinsiderAug 6th, 2018

Mersana Therapeutics shares plummet 40% after patient death in cancer trial

Mersana Therapeutics Inc. said early Thursday that, after the company reported a patient death in its cancer drug trial, the Food and Drug Administrat.....»»

Category: topSource: marketwatchJul 19th, 2018

Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. read more.....»»

Category: blogSource: benzingaJul 17th, 2018

Global Blood Therapeutics is making a big gamble on its sickle cell drug

The company is betting that recent trial results, which were mostly positive, are enough to score a drug approval — and is pausing the trial......»»

Category: topSource: marketwatchJun 27th, 2018

Global Blood Therapeutics is gambling on its sickle cell drug — and investors aren’t happy

The results, which were mostly positive, should have pleased investors. But the company is betting they are enough to score a drug approval — and is pausing the trial......»»

Category: topSource: marketwatchJun 27th, 2018

Cara Therapeutics Rallies On Positive Opioid Receptor Agonist Trial Results

Cara Therapeutics Inc (NASDAQ: CARA) popped more than 32 percent Wednesday morning after management reported positive top-line data for a drug candidate.  read more.....»»

Category: blogSource: benzingaJun 27th, 2018

Global Blood Therapeutics shares drop after late-stage data for sickle cell disease treatment

Global Blood Therapeutics Inc. shares dropped as much as 12% in premarket trade on Wednesday after the company reported results for a late-stage trial of sickle cell disease therapy, and said that it met with the U.S. Food and Drug Ad.....»»

Category: topSource: marketwatchJun 27th, 2018

Nektar Plummets Amid Concern Over Cancer-Drug Trial Results

Nektar Therapeutics lost a third of its value in Monday trading after response rates in melanoma and kidney cancer patients decreased in a mid-stage trial of the company’s cancer drug in combination with Bristol-Myers Squibb Co.’s Opdivo......»»

Category: topSource: moneycentralJun 4th, 2018

CRISPR, Vertex say FDA puts brakes on upcoming gene editing trial

Cambridge startup CRISPR Therapeutics and Boston-based Vertex Pharmaceuticals said on Wednesday that the FDA has put on hold a highly anticipated upcoming trial of their experimental gene editing drug for sickle cell disease. CRISPR (Nasdaq: CRIS.....»»

Category: topSource: bizjournalsMay 30th, 2018

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Esperion Therapeutics shares were halted in premarket trading on Wednesday after the firm announced late-stage trial results for its cholesterol drug......»»

Category: blogSource: 247wallstMay 23rd, 2018

Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2018

Nabriva Therapeutics unveils positive results in bacterial pneumonia drug trial

Nabriva Therapeutics PLC on Monday reported positive results in a a late-stage trial of a treatment for bacterial pneumonia, saying the phase 3 trial of Lefamulin Evaluation Against Pneumonia (LE.....»»

Category: topSource: marketwatchMay 21st, 2018

Nabriva Therapeutics announces positive results in late-stage trial of bacterial pneumonia drug

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchMay 21st, 2018

Brainstorm Health: Allogene IPO, Medtronic Hack Concern, Pharmacy Gag Clause

Brainstorm Health Daily: October 11, 2018 Good afternoon, readers--This is Sy. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled .....»»

Category: europeSource: fortuneOct 11th, 2018

TG Therapeutics says ARR of 0.07 observed for all patients in Phase 2 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Biotech firm raises $54M to hunt for cancer drugs

Gotham Therapeutics, a Manhattan-based biotech company, has received $54 million in Series A financing to advance research into a novel method of finding oncology drug candidates. The research was... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkOct 10th, 2018

Crispr stock up 8% as company says FDA accepted new-drug application

Shares of Crispr Therapeutics AG rose mo.....»»

Category: topSource: marketwatchOct 10th, 2018

Texas Biomed’s Taiwan deal a global endorsement for SA institute

An agreement with an Asian drug development company is expected to open international doors for the Alamo City institute......»»

Category: topSource: bizjournalsOct 10th, 2018